Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Immunization with HLA-A2 Peptides and IMP321 in Disease-Free Melanoma
NCT00365937Phase 2Terminated
- Start
- Aug 2006
- Primary completion
- Dec 2013
- Modality
- Prophylactic Vaccines, Therapeutic Vaccines, Fc-Fusion Proteins
- Countries
- 1
01
Overview
A Phase 2 trial of eftilagimod alpha in melanoma. Started Aug 2006; status: terminated.
02
Drugs
eftilagimod alpha
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT00365937.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00365937.